Spectrum has announced that Fusilev (levoleucovorin injection) is expected to be available in mid-August 2008. Fusilev is a folate analog indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists.

For more information call (949) 788-6700 or visit www.spectrumpharm.com.